Selected article for: "IFN pretreatment and viral protein"
Author: Kumari G. Lokugamage; Adam Hage; Craig Schindewolf; Ricardo Rajsbaum; Vineet D. Menachery
Title: SARS-CoV-2 is sensitive to type I interferon pretreatment
  • Document date: 2020_3_9
    • ID: 2w0zr9c0_19
    Snippet: Vero E6 lack the capacity to produce IFN-I, but are able to respond to exogenous treatment 92 (23). Following pretreatment with IFN-I, SARS-CoV infection has a modest reduction in viral 93 titer (1.5 log plaque forming units (PFU) as compared to untreated control 24 hours post 94 infection (Fig. 1B) . However, by 48 hours, SARS-CoV has nearly equivalent viral yields as the 95 untreated conditions (7.2 log PFU versus 7.5 log PFU). In contrast, SAR.....
    Document: Vero E6 lack the capacity to produce IFN-I, but are able to respond to exogenous treatment 92 (23). Following pretreatment with IFN-I, SARS-CoV infection has a modest reduction in viral 93 titer (1.5 log plaque forming units (PFU) as compared to untreated control 24 hours post 94 infection (Fig. 1B) . However, by 48 hours, SARS-CoV has nearly equivalent viral yields as the 95 untreated conditions (7.2 log PFU versus 7.5 log PFU). In contrast, SARS-CoV-2 shows a 96 significant reduction in viral replication following IFN-I treatment. At both 24 and 48 hours post 97 infection, SARS-CoV-2 had massive 3-log (24 HPI) and 4-log (48 HPI) drops in viral titer as 98 compared to control untreated cells. Finally, we examined viral protein production finding a 99 major deficit in nucleocapsid protein production in IFN-I treated cells following SARS-CoV-2 100 infection (Fig. 1C) . In contrast, viral proteins were robustly expressed for SARS-CoV-2 in 101 untreated cells and for SARS-CoV in both conditions. Together, the results demonstrate a clear 102 sensitivity to a primed IFN-I response in SARS-CoV-2, which is not observed with SARS-CoV. 103 SARS-CoV-2 fails to attenuate STAT1 phosphorylation and ISG production. 104

    Search related documents:
    Co phrase search for related documents
    • exogenous treatment and IFN treatment: 1, 2, 3, 4, 5, 6, 7, 8
    • IFN nucleocapsid protein production and nucleocapsid protein: 1, 2
    • IFN nucleocapsid protein production and nucleocapsid protein production: 1, 2
    • IFN nucleocapsid protein production and protein production: 1, 2
    • IFN pretreatment and ISG phosphorylation: 1, 2, 3, 4
    • IFN pretreatment and protein production: 1, 2, 3
    • IFN produce and nucleocapsid protein: 1
    • IFN produce and plaque forming: 1
    • IFN produce and protein production: 1, 2, 3, 4
    • IFN treatment and ISG phosphorylation: 1
    • IFN treatment and nucleocapsid protein: 1
    • IFN treatment and protein production: 1, 2
    • ISG phosphorylation and protein production: 1
    • ISG phosphorylation production and protein production: 1
    • log PFU plaque forming unit and PFU plaque forming unit: 1, 2
    • log PFU plaque forming unit and plaque forming: 1, 2
    • log PFU plaque forming unit and plaque forming unit: 1, 2
    • nucleocapsid protein and PFU plaque forming unit: 1
    • nucleocapsid protein and plaque forming: 1, 2